|
186 Products |
| 186 Products |
|
1696 Diseases |  |
95004 News |  |
| «12...271272273274275276277278279280281...10661067» |
- | hydrocortisone / Generic mfg.
Journal: Professional practices in the management of adrenal insufficiency in two tertiary referral hospitals (Tunis, Tunisia). (Pubmed Central) - Sep 2, 2022
physician practice in the management of AI need to be improved.
- | dexamethasone / Generic mfg., cyclosporine / Generic mfg.
Journal, HEOR: Comparing Kidney Health Outcomes in Children, Adolescents, and Adults With Focal Segmental Glomerulosclerosis. (Pubmed Central) - Sep 2, 2022
The median time to the composite end point was 5.7 years (IQR 1.6-15.2 years), with hazard ratio estimates for children vs adults of 1.12 (95% CI, 0.83-1.52) and adolescents vs adults of 1.06 (95% CI, 0.75-1.50). In this study, the association of FSGS with kidney survival and functional outcomes was comparable at all ages.
- | methimazole / Generic mfg.
Journal: Concomitant methimazole-induced agranulocytosis and cholestatic jaundice in a young woman. (Pubmed Central) - Sep 2, 2022
ANC and bilirubin improved over a 2-week hospital course. She was discharged on a temporary regimen of propranolol, dexamethasone and potassium iodide until she was able to undergo successful thyroidectomy for definitive management of Graves' disease outpatient.
- || cisplatin / Generic mfg.
Clinical, Journal, CINV: Therapeutic effect of low frequency electric pulse therapy on cisplatin-based chemotherapy-induced nausea and vomiting in patients with lung adenocarcinoma: A prospective controlled study. (Pubmed Central) - Sep 2, 2022
The side effects had no difference between the 2 groups. The LFEPT can significantly ameliorate CINV in patients with lung adenocarcinoma, which is worthy of clinical application.
- || Review, Journal: Thyroid storm complicated by corpus callosum infarction in a young patient: A case report and literature review. (Pubmed Central) - Sep 2, 2022
The LFEPT can significantly ameliorate CINV in patients with lung adenocarcinoma, which is worthy of clinical application. Careful physical examination should be performed in patients with thyroid storm, and head imaging examination should be improved for the early detection of cerebral infarction.
- | dexamethasone / Generic mfg.
Journal: Dexamethasone and MicroRNA-204 Inhibit Corneal Neovascularization. (Pubmed Central) - Sep 1, 2022
The role of Dex in attenuating CNV may be partly attributed to miR-204. MiR-204 may be a potential therapeutic target in alkali burn-induced CNV.
- | dexamethasone / Generic mfg., hydrocortisone / Generic mfg.
Journal: Current concepts of corticosteroids use for prevention of bronchopulmonary dysplasia. (Pubmed Central) - Sep 1, 2022
Hydrocortisone administration in very preterm infants does not appear to be associated with any neurotoxic effects, even if its efficacy in the prevention and treatment of BPD has yet to be clearly demonstrated...A positive effect on BPD prevention occurs when budesonide is nebulized and intratracheally instilled with surfactant, but more data are required to establish safety and efficacy in preterm newborns. Additional studies are still needed before the chronic lung disease issue and its related challenges can be solved.
- ||| dexamethasone / Generic mfg.
Clinical: We should explore the role of dexmed and dexamethasone for caudal including the safety profile.. (Twitter) - Sep 1, 2022
- Is International Reference Pricing Applied Consistently at Pharmaceutical Price Re-Evaluation for Retail and Specialty Products? (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_2547;
Also, prices of retail products are generally more aligned with IRP rules than specialty products. It would be interesting to continue to monitor these prices to see if IRP is applied more stringently at national price re-evaluations.
- salbutamol/beclomethasone / Generic mfg.
Budget Impact of Maintenance and Reliever Therapy With Budesonide-Formoterol Combination in the Treatment of Moderate Asthma in Costa Rica (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_2508;
Salbutamol and beclomethasone have 200 doses, Bud-Form has 120 doses, and formoterol has 60 doses... In Costa Rica, the total budget impact over three years due to the introduction of Bud-Form was $202.653 less expensive than SoC in patients with moderate asthma.
- Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma, Bevespi Aerosphere (formoterol/glycopyrrolate) / AstraZeneca
Economic Analysis of New Single-Inhaler Triple Therapies in Patients With COPD in the UK (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_2456;
Efficacy estimates were derived from a frequentist network meta-analysis, which compared FF/UMEC/VI with budesonide 320 µg/glycopyrronium/formoterol (BUD320/GLY/FOR), BUD160/GLY/FOR and beclomethasone dipropionate (BDP)/FOR/GLY (Ismaila, 2022 Adv Ther, in press). Based on this analysis, FF/UMEC/VI is a dominant treatment option compared with BUD/GLY/FOR (both dosages) and BDP/FOR/GLY for the treatment of COPD patients in the UK.
- Breztri Aerosphere (budesonide/formoterol fumarate/glycopyrronium) / AstraZeneca
Budget Impact Analysis of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate for COPD in the Italian Healthcare System (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_2428;
P3
In patients with moderate-to-very severe COPD, BGF decreased total costs when used in place of other triple therapies, with a total saving of €9,051,853. BGF is a clinically effective and cost-saving treatment from the perspective of the Italian healthcare system.
- salbutamol/beclomethasone / Generic mfg.
Budget Impact of Anti-Inflammatory Reliever Therapy With Budesonide-Formoterol Combination in the Treatment of Mild Asthma in Panama (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_2406;
All inhalers have 120 inhalations, except beclomethasone and salbutamol, which have 200... In Panama, the total budget impact over three years due to the introduction of Bud-Form as needed was $381.787 less expensive than SoC in patients with mild asthma.
- methylprednisolone sodium succinate / Generic mfg.
Systematic Review on Cost and Healthcare Resource Utilization in Immunoglobulin A Nephropathy (IgAN) (Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_2304;
There is scarce evidence on cost and resource use in IgAN patients. Existing evidence shows that current treatments like immunosuppressants and tonsillectomy are burdensome to the healthcare system and this warrants the need for improved, disease-specific therapy in IgAN.
- Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
Assessing the Validity of Netherlands Linked Routine Healthcare Resource Utilisation Data in the Investigation of Single-Inhaler Triple Therapy Effectiveness (INTREPID Trial) (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_2295;
Linked HCRU data were available for INTREPID patients with greater granularity than data generally available from prospectively collected patient recall of HCRU in pragmatic studies. Future studies should consider using linked routine hospital data alongside prospectively collected data in pragmatic trials in routine practice in the Netherlands.
- Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
Clinical and Economic Benefits of Prompt Initiation of Single-Inhaler Triple Therapy in COPD Patients in England Following an Exacerbation (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_2098;
Prompt initiation of FF/UMEC/VI following a COPD exacerbation was associated with fewer subsequent exacerbations and hospital readmissions and lower costs relative to delayed initiation. Benefits were seen with each day of earlier initiation, suggesting the optimal timing for initiation of FF/UMEC/VI may be shortly after index exacerbation.
- salbutamol/beclomethasone / Generic mfg.
Budget Impact of Anti-Inflammatory Reliever Therapy With Budesonide-Formoterol Combination in the Treatment of Mild Asthma in Costa Rica (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1935;
All inhalers have 120 inhalations, except beclomethasone and salbutamol, which have 200... In Costa Rica, the total budget impact over three years due to the introduction of Bud-Form as needed was $231.888 less expensive than SoC in patients with mild asthma.
- Darzalex (daratumumab) / J&J
Real-World Outcomes for the Treatment of Relapsed/Refractory Multiple Myeloma With Daratumumab: A Systematic Literature Review (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1878;
Of the publications on RRMM, 16 reported data on daratumumab monotherapy, 7 on daratumumab+lenalidomide+dexamethasone (D-Rd), 7 on daratumumab+bortezomib+dexamethasone (D-Vd), 4 on daratumumab+pomalidomide+dexamethasone (D-Pd), and 14 as part of a pooled therapy (some publications reported >1 daratumumab regimen)... These findings confirm and provide certainty that in a real-world setting, daratumumab is effective across different patient populations with RRMM regardless of patient disease characteristics or clinical features.
- Rinvoq (upadacitinib) / AbbVie
Budget Cap With Pay Back As Managed Entry Agreement Policy: Bulgarian Example for Rheumatology Medicines (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1800;
Only the budget for NSADs and non-biological products decreased. On opposite budget for biologicals increased but their prescribing increased which shows that most patients can benefit.
- dexamethasone / Generic mfg., lenalidomide / Generic mfg.
The Disparity in the Utilization of Drugs for Multiple Myeloma Using Real-World Data in the US (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1731;
OBJECTIVES: To explore the disparity in utilization of recommended first-line regimen of Dexamethasone and Lenalidomide in the new multiple myeloma patients This study included patients diagnosed with multiple myeloma between 1st Jan 2017 to 31st Dec 2019 with ICD-9 and ICD-10-CM diagnosis recorded in the Optum® de-identified Market Clarity Dataset, which links medical and pharmacy claims with EHR data from providers across the continuum of care. Blacks and Asians had lower access to Rd first-line regimen in comparison to Whites.
- Mekinist (trametinib) / Novartis, Tafinlar (dabrafenib) / Novartis
A Retrospective Single-Center Study to Evaluate the Real-World Clinical Outcomes and Healthcare Resource Utilization in Chinese Patients with BRAF-Mutant Non-Small Cell Lung Cancer (Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1714;
The study demonstrates better clinical benefit of D+T therapy than other therapies for Chinese BRAF-muted NSCLC patients. Use of D+T might help to reduce healthcare resource utilization.
- Darzalex (daratumumab) / J&J, Ninlaro (ixazomib) / Takeda
Living Network Meta-Analysis for Up-to-Date Comparative Effectiveness: A Case Study in Multiple Myeloma Maintenance (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1689;
P3
This study demonstrated the utility of an interactive NMA tool, which replicated and updated an existing analysis in a few minutes. This reliable tool can help decision makers stay current with comparative effectiveness of new and existing treatments.
- salbutamol/beclomethasone / Generic mfg.
Budget Impact of Maintenance and Reliever Therapy With Budesonide-Formoterol Combination in the Treatment of Moderate Asthma in Honduras (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_955;
Salbutamol and beclomethasone have 200 doses, Bud-Form has 120 doses, and formoterol has 60 doses... In Honduras, the total budget impact over three years due to the introduction of Bud-Form SMART was $1’858.202 less expensive than SoC in patients with moderate asthma.
- Darzalex Faspro (daratumumab/hyaluronidase) / J&J
Modelling Time and Costs Associated With Daratumumab Treatment Delivery in the Home Care Setting Versus the Hospital in Spain to Understand Potential Benefits to Patients and Hospitals (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_879;
This research aims to evaluate if daratumumab SC injection for multiple myeloma in the home care setting can provide value to patients and hospitals in terms of time spent on treatment and associated costs, versus receiving treatment in the Spanish hospital setting...Patient characteristics were assigned probabilistically to determine eligibility for home treatment, and doses were scheduled according to product label for patients treated in combination with lenalidomide and dexamethasone... The results of this simulation have demonstrated the benefits to patients and hospitals of engaging in daratumumab home treatment programs.
- salbutamol/beclomethasone / Generic mfg.
Budget Impact of Anti-Inflammatory Reliever Therapy With Budesonide-Formoterol Combination in the Treatment of Mild Asthma in Honduras (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_763;
All inhalers have 120 inhalations, except beclomethasone and salbutamol, which have 200... In Honduras, the total budget impact over three years due to the introduction of Bud-Form as needed was $342.987 less expensive than SoC in patients with mild asthma.
- salbutamol/beclomethasone / Generic mfg.
Budget Impact of Maintenance and Reliever Therapy With Budesonide-Formoterol Combination in the Treatment of Moderate Asthma in Panama (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_490;
Salbutamol and beclomethasone have 200 doses, Bud-Form has 120 doses, and formoterol has 60 doses... In Panama, the total budget impact over three years due to the introduction of Bud-Form SMART was $1’477.064 less expensive than SoC in patients with moderate asthma.
- Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
Reduced Health Care Resource Utilisation and Costs Following a Switch From Multiple-Inhaler to Once-Daily Single-Inhaler Triple Therapy in COPD Patients in a Real-World Primary Care Setting in England (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_422;
COPD patients who switched from MITT to once-daily SITT FF/UMEC/VI had lower COPD-related HCRU and costs 6-months following the switch compared with 6-months pre-switch. The long-term benefits of switching from MITT to SITT requires further investigation.
- dexamethasone / Generic mfg., thalidomide / Generic mfg.
SARS-COV-1 Omicron BA.1 Associated Impact on Quality of Life and Medication Adherence of Multiple Myeloma Patients Treated With Thalidomide or Its Analogues Plus Dexamethasone 1JAN-31MAR2022 (Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_403;
Pre- and During-CoVID-19 OBA.1 MPR were higher than the industry standard of >0.9.5 Ta have FDA REMS requirements which may have contributed to MPRs being > standard.6 On average, patients reported QoL on Mobility, Self-Care and Anxiety/Depression worsened but improved on Usual Activities and Pain/Discomfort. Over-all Health rating improved slightly.
- Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
Assessing the Validity of English Linked Routine Healthcare Resource Utilisation Data in the Investigation of Triple Therapy Effectiveness (INTREPID Trial) (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_383;
Future studies should consider the benefits of using linked routine hospital data alongside prospectively collected data in pragmatic trials in routine practice in England. Funding: GSK (study 206854)
- Jorveza (budesonide orodispersible tablets) / Dr Falk
Comparative Cost-Utility Analysis of Budesonide and the Six Food Elimination Diet (SFED) for the Prophylaxis of Patients with Eosinophilic Esophagitis (EoE) in the Austrian Setting (Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_348;
Funding: GSK (study 206854) In terms of cost-effectiveness, budesonide orodispersible tablets provide good value for money to the Austrian healthcare system as they provide an average of four months of quality of life to patients with EoE at a highly cost-effective price when compared to the SFED.
- Darzalex (daratumumab) / J&J, Sarclisa (isatuximab-irfc) / Sanofi
Should Health Technology Assessment (HTA) Bodies Utilize Living HTA Tools? Validation of LiveSLR® and LiveNMA™ Tools Using ICER’S Class Review in Relapsed Refractory Multiple Myeloma (RRMM) (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_345;
Living HTA can only become a reality through the adoption of automated tools and platforms such as LiveSLR®/LiveNMA™. More research is required to understand payer’s challenges in routine integration of such tools in their processes.
- || fluticasone / Generic mfg.
Yesterdays news wrt systemic effects of ICS and published in low impact journal 2.7 . Lipophilic ICS like fluticasone cause more dose related systemic effects than BUD or BDP . As I always tell my students never use the F word . (Twitter) - Sep 1, 2022
- ||| Darzalex Faspro (daratumumab and hyaluronidase-fihj) / J&J, Talvey (talquetamab-tgvs) / J&J
Trial completion date, Combination therapy: MonumenTAL-3: A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment (clinicaltrials.gov) - Sep 1, 2022
P3, N=810, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
More research is required to understand payer’s challenges in routine integration of such tools in their processes. Trial completion date: Apr 2029 --> Sep 2029
- ||| Darzalex (daratumumab) / J&J, Tecvayli (teclistamab-cqyv) / Genmab, J&J
Trial completion date, Trial initiation date, Trial primary completion date: MASTER-2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (clinicaltrials.gov) - Sep 1, 2022
P2, N=300, Not yet recruiting, Sponsor: University of Alabama at Birmingham
Trial completion date: Apr 2029 --> Sep 2029 Trial completion date: Apr 2027 --> Dec 2027 | Initiation date: Aug 2022 --> Dec 2022 | Trial primary completion date: Apr 2026 --> Dec 2026
- | ketorolac / Generic mfg.
Trial completion date, Trial primary completion date: Effect of Ketorolac on Post Adenotonsillectomy Pain (clinicaltrials.gov) - Sep 1, 2022
P4, N=120, Recruiting, Sponsor: Emory University
Trial completion date: Apr 2027 --> Dec 2027 | Initiation date: Aug 2022 --> Dec 2022 | Trial primary completion date: Apr 2026 --> Dec 2026 Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Aug 2022 --> Aug 2023
- | dexamethasone injection / Generic mfg.
New trial, Surgery: Comparison Between the Quadratus Lumborum Block ,Erector Spinae Plane Block in Lower Abdominal Surgery (clinicaltrials.gov) - Sep 1, 2022
P=N/A, N=48, Recruiting, Sponsor: Fayoum University Hospital
- | Journal: Structure-based virtual screening, molecular dynamics and binding affinity calculations of some potential phytocompounds against SARS-CoV-2. (Pubmed Central) - Aug 31, 2022
In-silico approaches also predict this molecule to have good solubility, pharmacodynamic property and target accuracy through MD simulation and ADME studies. These hit molecules niazinin, vitexin, glucoraphanin also obey Lipinski's rule along with their stable binding towards target protein of the virus, which makes them suitable for further biochemical and cell-based assays followed by clinical investigations to highlight their potential use in COVID-19 treatment.Communicated by Ramaswamy H. Sarma.
- | dexamethasone / Generic mfg.
Journal: A Novel Methodology Using Dexamethasone to Induce Neuronal Differentiation in the CNS-Derived Catecholaminergic CAD Cells. (Pubmed Central) - Aug 31, 2022
In addition, RNA-sequencing and qPCR data demonstrate that several genes involved in proliferation, neuronal differentiation, and survival pathways were differentially expressed in the Dex-differentiated cells. This is the first study to reveal Dex as a novel differentiation methodology used to generate postmitotic neuronal CAD cells, which may be utilized as an in vitro neuronal model for cellular and molecular neurobiology research.
- || remdesivir / Generic mfg., dexamethasone / Generic mfg.
Clinical, Journal: Optimal timing of remdesivir initiation in hospitalized COVID-19 patients administered with dexamethasone. (Pubmed Central) - Aug 31, 2022
This is the first study to reveal Dex as a novel differentiation methodology used to generate postmitotic neuronal CAD cells, which may be utilized as an in vitro neuronal model for cellular and molecular neurobiology research. Initiation of remdesivir prior to or simultaneously with dexamethasone was associated with significantly shorter time to clinical improvement and positive IgG antibody, lower risk of in-hospital death, in addition to shorter length of hospital stay in patients with moderate COVID-19.
- | dexamethasone / Generic mfg.
Journal: Understanding the Potential Impact of Different Drug Properties On SARS-CoV-2 Transmission and Disease Burden: A Modelling Analysis. (Pubmed Central) - Aug 31, 2022
Advances in the treatment of COVID-19 to date have been focused on hospitalized-patients and predicated on an assumption of adequate access to supportive care. Therapeutics delivered earlier in the course of infection that reduce the need for healthcare or reduce infectiousness could have significant impact, and research into their efficacy and means of delivery should be a priority.
- | dexamethasone / Generic mfg.
Preclinical, Journal: Dose-dependent and time-dependent metabolic, hemodynamic, and redox disturbances in dexamethasone-treated Wistar rats. (Pubmed Central) - Aug 31, 2022
Therapeutics delivered earlier in the course of infection that reduce the need for healthcare or reduce infectiousness could have significant impact, and research into their efficacy and means of delivery should be a priority. Doses of 1,000 µg/kg for subchronic and 100 µg/kg for chronic treatment exhibited similar effects and are the best doses to respective time frames to induce the model.
- | remdesivir / Generic mfg., dexamethasone / Generic mfg.
Journal: Remdesivir plus dexamethasone versus dexamethasone alone for the treatment of COVID-19 patients requiring supplemental O2 therapy: a prospective controlled non-randomized study. (Pubmed Central) - Aug 31, 2022
Doses of 1,000 µg/kg for subchronic and 100 µg/kg for chronic treatment exhibited similar effects and are the best doses to respective time frames to induce the model. Remdesivir/dexamethasone treatment is associated with significant reduction in mortality, length of hospitalization, and faster SARS-CoV-2 clearance, compared to dexamethasone alone.
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Vision loss due to IgG4-related disease of the skull base, complicated by a mucocele of the sphenoid sinus. (Pubmed Central) - Aug 31, 2022
It may even be the only option to prevent irreversible damage to the surrounding tissues. A multidisciplinary approach in the management of sino-orbital IgG4-RD is therefore warranted.
- | Olumiant (baricitinib) / Incyte, Eli Lilly, Arbidol (umifenovir) / Pharmstandard
Journal: Therapeutic strategies for COVID-19 patients: An update. (Pubmed Central) - Aug 31, 2022
Baricitinib, the Janus kinase (JAK) 1/2 inhibitor, is also an attractive candidate due to its properties as a potent anti-inflammatory agent and its hypothesized offtarget antiviral effects against SARS-CoV-2...Importantly, with the number of patients increasing daily, there is an urgent need for effective therapeutic intervention. In this review, we expatiated on several strategies deployed for the treatment of COVID-19 infection.
- | dexamethasone / Generic mfg.
Journal: Efficacy of Corticosteroid Therapy in Non-severe COVID-19 Patients with Severe Risk Factors who do not Require Supplemental Oxygen. (Pubmed Central) - Aug 31, 2022
The latest World Health Organization guidance recommends against corticosteroid treatment for patients with non-severe COVID-19. In this report, early administration of corticosteroids during the non-critical phase, when oxygen supplementation was not required, was associated with early improvement and prevention of severe disease in patients with risk factors for severe COVID-19 and worsening clinical symptoms.
- | dexamethasone injection / Generic mfg.
Journal: Intravitreal dexamethasone: variation of surgical technique and prevention of ocular complications with ASOCT follow-up. (Pubmed Central) - Aug 31, 2022
Speaking of intravitreal injections of slow-release dexamethasone, the technique that involves moving the conjunctiva and a beveled or angled sclerotomy after a careful choice of the injection site, paying attention to vary the quadrant involved with each puncture, reduces the number of days of closure of the sclera via and the scleral damage, thus protecting the patient from complications. For the future, it is hoped that the operating microscope and intraoperative OCT will be used on every occasion.
- | prednisolone / Generic mfg.
Preclinical, Journal: Effect of combination treatment with Lactobacillus rhamnosus and corticosteroid in reducing airway inflammation in a mouse asthma model. (Pubmed Central) - Aug 31, 2022
For the future, it is hoped that the operating microscope and intraoperative OCT will be used on every occasion. LGG may reduce the dosage of prednisolone and thus may be beneficial in the treatment of asthma.
- | dexamethasone / Generic mfg., ondansetron / Generic mfg.
Journal, HEOR: Cost-effectiveness analysis of aprepitant-based anti-emetic regimen for children receiving highly emetogenic chemotherapy: Individual patient data analysis of a randomized trial. (Pubmed Central) - Aug 31, 2022
Aprepitant-based anti-emetic regimen is cost-effective for children receiving HEC. It results in overall cost savings and reduced healthcare-resource utilization.
- | dexamethasone / Generic mfg., disulfiram / Generic mfg.
Journal: Multiple deadlocks in the development of nonprofit drugs. (Pubmed Central) - Aug 31, 2022
Based on my own experience with repurposing the alcohol-abuse drug disulfiram (Antabuse) for cancer, I identify at least four serious deadlocks to development of nonprofit drugs. All of these obstacles should be addressed to leverage the potential of the COVID-19 pandemic for better future healthcare systems in all countries around the world.
- ||| Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis, Merck (MSD)
Enrollment open, Real-world evidence, Real-world: A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura® (clinicaltrials.gov) - Aug 31, 2022
P=N/A, N=600, Recruiting, Sponsor: Novartis Pharmaceuticals
All of these obstacles should be addressed to leverage the potential of the COVID-19 pandemic for better future healthcare systems in all countries around the world. Not yet recruiting --> Recruiting